Stephen Saletan
About
In The Last Decade
Stephen Saletan
32 papers receiving 774 citations
Peers
Comparison fields: 5 of 96
- Oncology 363
- Epidemiology 280
- Molecular Biology 205
- Hematology 191
- Neurology 154
Countries citing papers authored by Stephen Saletan
This map shows the geographic impact of Stephen Saletan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Saletan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Saletan more than expected).
Fields of papers citing papers by Stephen Saletan
This network shows the impact of papers produced by Stephen Saletan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Saletan. The network helps show where Stephen Saletan may publish in the future.
Co-authorship network of co-authors of Stephen Saletan
This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Saletan. A scholar is included among the top collaborators of Stephen Saletan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Saletan. Stephen Saletan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 86 | |
| 3 | Safety and Quality-Of-Life (QOL) Assessments in the Open-Label, Multicenter, Phase 3b, Expanded Access Study of Everolimus in Patients with Advanced Neuroendocrine Tumors (NET) | 2 |
| 4 | 30 | |
| 5 | 2 | |
| 6 | 2 | |
| 7 | 94 | |
| 8 | 9 | |
| 9 | Analysis of Progression-Free Survival (PFS) by Prior Chemotherapy Use and Updated Safety in RADIANT-3: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Everolimus in Patients with Advanced Low- or Intermediate-Grade Pancreatic Neuroendocrine Tumors (pNET) | 2 |
| 10 | 20 | |
| 11 | 2 | |
| 12 | 1 | |
| 13 | 6 | |
| 14 | 10 | |
| 15 | 45 | |
| 16 | Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. | 145 |
| 17 | 28 | |
| 18 | 34 | |
| 19 | 4 | |
| 20 | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.